Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | 68.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.01% |
| Mar 31, 2026 | 124.87% |
| Dec 31, 2025 | 187.13% |
| Sep 30, 2025 | 1,606.13% |
| Jun 30, 2025 | 443.54% |
| Mar 31, 2025 | 459.92% |
| Dec 31, 2024 | 333.99% |
| Sep 30, 2024 | -113.16% |
| Jun 30, 2024 | 238.07% |
| Mar 31, 2024 | 193.44% |
| Dec 31, 2023 | 137.36% |
| Sep 30, 2023 | -72.63% |
| Jun 30, 2023 | 52.16% |
| Mar 31, 2023 | 88.42% |
| Dec 31, 2022 | 38.70% |
| Sep 30, 2022 | 317.66% |
| Jun 30, 2022 | 79.83% |
| Mar 31, 2022 | 8.17% |
| Dec 31, 2021 | 54.16% |
| Sep 30, 2021 | 16.93% |